Early Induction Outcomes in Acute Myeloid Leukemia: Impact of Clinical Status, Infectious Complications, Cardiometabolic Comorbidities, and Diagnostic Features in a Cohort Study.
La Clinica Terapeutica · 01.09.2026 · 177 (5) · 1117-1130
DOI: 10.7417/ct.2026.2113 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift La Clinica Terapeutica, erschienen am 01.09.2026. Verfasst von Ahmed Akef und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Induction Chemotherapy.
Abstract (Originalsprache)
Background
Induction chemotherapy outcomes in acute myeloid leukemia (AML) remain suboptimal in many low- and middle-income countries due to delayed diagnosis, limited supportive care resources, and treatment-related complications. Data regarding predictors of induction outcomes in resource-limited settings remain scarce. This study aimed to evaluate day-28 induction outcomes and identify clinical, laboratory, infectious, comorbidity-related, and diagnostic factors associated with unfavorable induction outcomes in adult AML patients.
Methods
This observational cohort study included 90 adult patients with newly diagnosed non-acute promyelocytic leukemia (non-APL) AML who received induction chemotherapy between January 2020 and December 2024 at Al-Azhar University Hospitals, Cairo, Egypt. Day-28 induction outcomes were categorized as complete remission (CR), refractory disease (R), or induction-related death (IID). Unfavorable induction outcome was defined as refractory disease or IID. Baseline demographic, clinical, laboratory, infectious, comorbidity, immunophenotypic, and cytogenetic variables were analyzed using univariate and multivariate logistic regression models.
Results
Among the 90 patients, 53 (58.9%) achieved CR, 20 (22.2%) had refractory disease, and 17 (18.9%) experienced IID. Poor ECOG performance status (≥2) was significantly associated with unfavorable induction outcomes in both univariate (OR = 4.58, 95% CI: 1.74 - 12.08, P = 0.002) and multivariate analyses (OR = 3.96, 95% CI: 1.39 - 11.27, P = 0.010). Severe thrombocytopenia (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Geriatric Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Department of Internal Medicine, Hematology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Internal Medicine Department, Faculty of Medicine, Menoufia University, Egypt.
Zitieren
APA
Akef, A., Aly, M., Morsy, M. H., Amro, O. A. E. A., Elsayed, F. M., Elkholy, H. Y., Barakat, M., Emam, L., Ahmed, A. N., El-Attar, L. M., Matta, P. M. T., Abdelhamid, S. M., Ahmed, W. M. K., Ibrahim, E., & Shalaby, N. (2026). Early Induction Outcomes in Acute Myeloid Leukemia: Impact of Clinical Status, Infectious Complications, Cardiometabolic Comorbidities, and Diagnostic Features in a Cohort Study. La Clinica Terapeutica, 177(5), 1117-1130. https://doi.org/10.7417/ct.2026.2113
Vancouver
Akef A, Aly M, Morsy MH, Amro OAEA, Elsayed FM, Elkholy HY, et al. Early Induction Outcomes in Acute Myeloid Leukemia: Impact of Clinical Status, Infectious Complications, Cardiometabolic Comorbidities, and Diagnostic Features in a Cohort Study. La Clinica Terapeutica. 2026;177(5):1117-1130. doi:10.7417/ct.2026.2113
BibTeX
@article{Akef2026,
author = {Akef, Ahmed and Aly, Maysa and Morsy, Mohamed Hanafy and Amro, Ola Abd Elfattah Ali and Elsayed, Fatma M and Elkholy, Heba Yahia and Barakat, Murad and Emam, Loai and Ahmed, Amira N and El-Attar, Lama M and Matta, Peter Makram Thabet and Abdelhamid, Salwa M and Ahmed, Walid Mohamed Kamel and Ibrahim, Eiman and Shalaby, Neveen},
title = {Early Induction Outcomes in Acute Myeloid Leukemia: Impact of Clinical Status, Infectious Complications, Cardiometabolic Comorbidities, and Diagnostic Features in a Cohort Study},
journal = {La Clinica Terapeutica},
year = {2026},
volume = {177},
number = {5},
pages = {1117--1130},
doi = {10.7417/ct.2026.2113}
}
EUVIMED